View Future GrowthFirebrick Pharma 과거 순이익 실적과거 기준 점검 0/6Firebrick Pharma은 연평균 11.3%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 5.8%의 비율로 증가했습니다. 매출은 연평균 9%의 비율로 감소했습니다.핵심 정보11.29%순이익 성장률24.52%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률31.22%매출 성장률-9.02%자기자본이익률-126.43%순이익률-596.85%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공고 • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공고 • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listing공고 • Sep 29Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025.공고 • Aug 30Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공고 • Aug 26+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공고 • Jun 26Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,095,238 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공고 • Mar 05Firebrick Pharma Limited announced that it expects to receive AUD 1.1 million in funding from Pharma Nutria N.a. (metro Manila Luzon), Inc.Firebrick Pharma Limited announce that it has secured an investment from Pharma Nutria N.A., Inc to issue 11,578,947 ordinary shares at a price of AUD 0.095 per share for gross proceeds of AUD 1,099,999.965 on March 4, 2025. The Shares are subject to a voluntary escrow of 12 months. The 11,578,947 Shares will represent 5.2% of all Firebrick shares outstanding and therefore PNAI will become a substantial shareholder in Firebrick.공고 • Oct 29Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024.공고 • Oct 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,885,454 Price\Range: AUD 0.055 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listing공고 • Sep 12+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,363,636 Price\Range: AUD 0.055Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).공고 • Sep 15Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common ColdFirebrick Pharma Limited announced that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray as a treatment for the common cold. The analysis has shown that the trial did not meet its primary endpoint, which was the impact of Nasodine on overall cold severity (GSS) in subjects with a confirmed viral infection (ITTi). Based on the reported results, the placebo (sterile water) performed better than Nasodine. In the QoL (`quality-of-life') measure (functional impairment caused by a cold), the results were also in favour of the placebo in the ITTi. Similar enigmatic results were seen in other population subsets. The results provided to the Company are shown in the table titled: Trial Headline Results Summary. These results are compared in summary form with the previous (2019) Phase 3 trial in the table titled: Phase 3 Trial Comparisons on Key Endpoints. The 2019 trial used the same protocol and treatment regimen as the current (2022-23) trialand both trials were robust Phase 3 trials. The 2019 trial took place in Australia, so a comparison of the results with the current trial for Australian sites only has been undertaken (not shown in summary tables). In the 2019 trial, the GSS benefit of Nasodine in the viral-infected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024). The reported results also appear to conflict with the Company's recently reported Phase 2 COVID-19 trial, where Nasodine treatment led to 100% clearance of the SARS-CoV-2 virus from the nasal passages. That result was significantly better than the placebo (p=0.028), which was the same water placebo as used in the 2022-23 Phase 3 trial. The Company is concerned that the results are so confounding, unexpected and at odds with previous data that there may be a systematic error or other issue in the data, and a detailed analysis is now underway to try to identify any causes of such an error. To that end, the Company is working with the Contract Research Organisation (CRO) responsible for trial governance and other service providers to thoroughly investigate the trial results. At this time, there is no evidence that the placebo and Nasodine treatments were switched during production, distribution or treatment.Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).공고 • Jul 22Firebrick Update on Administrative Appeals Tribunal ProcessFirebrick Pharma Limited announced that the scheduled conciliation meeting with the TGA (Therapeutic Goods Administration), which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023. The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine Nasal Spray ("Nasodine"). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached. This announcement was authorized for release by Dr. Peter Molloy, Executive Chairman, Firebrick Pharma Limited.공고 • May 16Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023, at 11:00 E. Australia Standard Time. Agenda: To consider the ratification of tranche 1 placement shares; to consider the issue of tranche 2 placement shares to related party Stephen Goodall; and to consider the issue of tranche 2 placement shares to related party Peter Molloy.Board Change • Mar 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Richard Treagus was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Firebrick Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CHIA:FRE 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-22130 Sep 250-32130 Jun 251-32131 Mar 251-22131 Dec 241-22130 Sep 242-12130 Jun 243-12231 Mar 242-32331 Dec 232-52430 Sep 231-62430 Jun 230-72431 Mar 231-62431 Dec 221-52430 Sep 221-52330 Jun 221-42231 Mar 221-32231 Dec 210-32130 Sep 210-32130 Jun 210-22130 Jun 201-10230 Jun 190-101양질의 수익: FRE 은(는) 현재 수익성이 없습니다.이익 마진 증가: FRE는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: FRE는 수익성이 없지만 지난 5년 동안 연평균 11.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 FRE의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: FRE은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-17.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: FRE는 현재 수익성이 없으므로 자본 수익률이 음수(-126.43%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/20 00:36종가2026/07/16 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Firebrick Pharma Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).
Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$13.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m (AU$411k revenue, or US$297k). Market cap is less than US$10m (AU$13.7m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rick Legleiter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.51692 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,636,603 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,638,298 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공고 • Mar 31Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,914,893 Price\Range: AUD 0.047 Discount Per Security: AUD 0.00282 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공고 • Oct 16Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.102 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: AUD 0.085 Transaction Features: Subsequent Direct Listing
공고 • Sep 29Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025Firebrick Pharma Limited, Annual General Meeting, Nov 26, 2025.
공고 • Aug 30Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공고 • Aug 26+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 1.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,222,222 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공고 • Jun 26Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,095,238 Price\Range: AUD 0.063 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공고 • Mar 05Firebrick Pharma Limited announced that it expects to receive AUD 1.1 million in funding from Pharma Nutria N.a. (metro Manila Luzon), Inc.Firebrick Pharma Limited announce that it has secured an investment from Pharma Nutria N.A., Inc to issue 11,578,947 ordinary shares at a price of AUD 0.095 per share for gross proceeds of AUD 1,099,999.965 on March 4, 2025. The Shares are subject to a voluntary escrow of 12 months. The 11,578,947 Shares will represent 5.2% of all Firebrick shares outstanding and therefore PNAI will become a substantial shareholder in Firebrick.
공고 • Oct 29Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024.
공고 • Oct 17Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,885,454 Price\Range: AUD 0.055 Discount Per Security: AUD 0 Transaction Features: Subsequent Direct Listing
공고 • Sep 12+ 1 more updateFirebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,363,636 Price\Range: AUD 0.055
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (improved from AU$0.04 loss in FY 2023). Net loss: AU$1.18m (loss narrowed 83% from FY 2023).
공고 • Sep 15Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common ColdFirebrick Pharma Limited announced that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray as a treatment for the common cold. The analysis has shown that the trial did not meet its primary endpoint, which was the impact of Nasodine on overall cold severity (GSS) in subjects with a confirmed viral infection (ITTi). Based on the reported results, the placebo (sterile water) performed better than Nasodine. In the QoL (`quality-of-life') measure (functional impairment caused by a cold), the results were also in favour of the placebo in the ITTi. Similar enigmatic results were seen in other population subsets. The results provided to the Company are shown in the table titled: Trial Headline Results Summary. These results are compared in summary form with the previous (2019) Phase 3 trial in the table titled: Phase 3 Trial Comparisons on Key Endpoints. The 2019 trial used the same protocol and treatment regimen as the current (2022-23) trialand both trials were robust Phase 3 trials. The 2019 trial took place in Australia, so a comparison of the results with the current trial for Australian sites only has been undertaken (not shown in summary tables). In the 2019 trial, the GSS benefit of Nasodine in the viral-infected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024). The reported results also appear to conflict with the Company's recently reported Phase 2 COVID-19 trial, where Nasodine treatment led to 100% clearance of the SARS-CoV-2 virus from the nasal passages. That result was significantly better than the placebo (p=0.028), which was the same water placebo as used in the 2022-23 Phase 3 trial. The Company is concerned that the results are so confounding, unexpected and at odds with previous data that there may be a systematic error or other issue in the data, and a detailed analysis is now underway to try to identify any causes of such an error. To that end, the Company is working with the Contract Research Organisation (CRO) responsible for trial governance and other service providers to thoroughly investigate the trial results. At this time, there is no evidence that the placebo and Nasodine treatments were switched during production, distribution or treatment.
Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)Full year 2023 results: AU$0.04 loss per share (further deteriorated from AU$0.033 loss in FY 2022). Net loss: AU$6.80m (loss widened 79% from FY 2022).
공고 • Jul 22Firebrick Update on Administrative Appeals Tribunal ProcessFirebrick Pharma Limited announced that the scheduled conciliation meeting with the TGA (Therapeutic Goods Administration), which was moderated by the Administrative Appeals Tribunal (AAT) took place in Sydney on 19 July 2023. The meeting between the parties was cordial with a frank exchange on the issues relating to the approval of Nasodine Nasal Spray ("Nasodine"). Confidential discussions between the parties are ongoing and Firebrick is hopeful that an agreement on the approval of Nasodine can be reached. This announcement was authorized for release by Dr. Peter Molloy, Executive Chairman, Firebrick Pharma Limited.
공고 • May 16Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023, at 11:00 E. Australia Standard Time. Agenda: To consider the ratification of tranche 1 placement shares; to consider the issue of tranche 2 placement shares to related party Stephen Goodall; and to consider the issue of tranche 2 placement shares to related party Peter Molloy.
Board Change • Mar 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Richard Treagus was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.